Skip to content
Search
Search
Close this search box.
Search
Search
Close this search box.
A phase 2 expansion study of ARV-766, a PROTAC® androgen receptor degrader, in metastatic castration-resistant prostate cancer
Daniel P Petrylak, et al.
February 16, 2023
ASCO Genitourinary Cancers Symposium
Download
Search
Search
Close this search box.
Our Science
PROTAC® Discovery Engine
Scientific Publications
Partnerships
About Us
Leadership
Board of Directors
Scientific Advisory Board
Pipeline and Research
Pipeline
Bavdegalutamide
Vepdegestrant
Neuroscience
Careers and Culture
Open Positions
Life in New Haven
Our Values
Benefits
Giving Back
Patients
Patients with Breast Cancer
Patients with Prostate Cancer
Clinical Trials
Expanded Access Policy
Investors and Media
Press Releases
Events and Presentations
Corporate Governance
Financials and SEC Filings
Annual Meeting
Stock Information
Analyst Coverage
Investor FAQs
Resources
Email Alerts
Contact Us
Contact Us
Linkedin-in
Twitter
Skip to content
